HOOK vs. IMUX, VLON, APLT, IPA, RZLT, SYRS, DMAC, CLNN, BLPH, and SLGL
Should you be buying Hookipa Pharma stock or one of its competitors? The main competitors of Hookipa Pharma include Immunic (IMUX), Vallon Pharmaceuticals (VLON), Applied Therapeutics (APLT), ImmunoPrecise Antibodies (IPA), Rezolute (RZLT), Syros Pharmaceuticals (SYRS), DiaMedica Therapeutics (DMAC), Clene (CLNN), Bellerophon Therapeutics (BLPH), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical preparations" industry.
Hookipa Pharma vs.
Hookipa Pharma (NASDAQ:HOOK) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, community ranking, media sentiment and profitability.
Hookipa Pharma has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Immunic has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500.
Hookipa Pharma has higher revenue and earnings than Immunic. Hookipa Pharma is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.
Immunic has a net margin of 0.00% compared to Hookipa Pharma's net margin of -416.94%. Hookipa Pharma's return on equity of -61.79% beat Immunic's return on equity.
52.3% of Hookipa Pharma shares are owned by institutional investors. Comparatively, 60.7% of Immunic shares are owned by institutional investors. 4.6% of Hookipa Pharma shares are owned by company insiders. Comparatively, 5.0% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Immunic received 12 more outperform votes than Hookipa Pharma when rated by MarketBeat users. Likewise, 68.18% of users gave Immunic an outperform vote while only 67.83% of users gave Hookipa Pharma an outperform vote.
In the previous week, Hookipa Pharma had 4 more articles in the media than Immunic. MarketBeat recorded 6 mentions for Hookipa Pharma and 2 mentions for Immunic. Hookipa Pharma's average media sentiment score of 0.30 beat Immunic's score of 0.28 indicating that Hookipa Pharma is being referred to more favorably in the media.
Hookipa Pharma currently has a consensus target price of $5.50, indicating a potential upside of 364.14%. Immunic has a consensus target price of $17.75, indicating a potential upside of 992.31%. Given Immunic's stronger consensus rating and higher possible upside, analysts plainly believe Immunic is more favorable than Hookipa Pharma.
Summary
Immunic beats Hookipa Pharma on 9 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HOOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hookipa Pharma Competitors List
Related Companies and Tools
